Multiple Sclerosis and Related Disorders

Exploratory clinical efficacy and patient-reported outcomes from NOVA: a randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.  104561. 2023

The nine hole peg test as an outcome measure in progressive MS trials.  69. 2023

COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes.  65. 2022

Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases.  63. 2022

The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.  61. 2022

Do physical activity, cardiorespiratory fitness, and subcortical brain structures explain reduced walking performance in older adults with multiple sclerosis?.  60. 2022

Measuring cognitive function by the SDMT across functional domains: Useful but not sufficient.  60. 2022

Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.  60. 2022

Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis.  59:103626. 2022

AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.  57. 2022

White matter tracts that overlap with the thalamus and the putamen are protected against multiple sclerosis pathology.  57. 2022

Demographic, clinical, and symptomatic correlates of subjective sleep quality in adults with multiple sclerosis.  55. 2021

Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study.  50. 2021

CSF plasmablasts differentiate MS from other neurologic disorders.  48. 2021

A longitudinal study of symptom botheration in Multiple Sclerosis..  46. 2020

Effect size – one size doesn't fit all.  46. 2020

Feasibility of improving dietary quality using a telehealth lifestyle intervention for adults with multiple sclerosis.  46. 2020

Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.  40. 2020

EFFECT size or statistical significance, where to put your money.  38. 2020

The priorities of neurologists for exercise promotion in comprehensive multiple sclerosis care.  38. 2020

Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis.  37. 2020

Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.  33:13-21. 2019

Evaluation of a web-based fall prevention program among people with multiple sclerosis.  31:151-156. 2019

The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments.  31:165-172. 2019

Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.  29:86-93. 2019

Use of eHealth and mHealth technology by persons with multiple sclerosis.  27:13-19. 2019

An introduction to Mendelian randomization with applications in neurology.  24:72-78. 2018

A survey of dietary characteristics in a large population of people with multiple sclerosis.  22:12-18. 2018

Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis.  22:103-107. 2018

Factors associated with excessive sitting time in multiple sclerosis.  21:71-77. 2018

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.  20:16-21. 2018

Examining the contributions of environmental quality to pediatric multiple sclerosis.  18:164-169. 2017

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.  18:95-102. 2017

Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis.  13:87-92. 2017

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.  12:70-78. 2017

A case-control study of dietary salt intake in pediatric-onset multiple sclerosis.  6:87-92. 2016

Relapses in multiple sclerosis: Relationship to disability.  6:10-20. 2016

Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.  4:546-554. 2015

Causes of death among persons with multiple sclerosis.  4:484-490. 2015

Impact of multiple sclerosis relapse: The NARCOMS participant perspective.  4:234-240. 2015

Risk tolerance to MS therapies: Survey results from the NARCOMS registry.  4:241-249. 2015

Regional gray matter atrophy in relapsing remitting multiple sclerosis: Baseline analysis of multi-center data.  4:124-136. 2015

Bifactor structure of clinical disability in relapsing multiple sclerosis.  3:176-185. 2014

Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab.  3:505-512. 2014

Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.  3:705-711. 2014

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S..  3:364-371. 2014

A retrospective review of lithium usage in veterans with multiple sclerosis.  2:327-333. 2013

Substantial burden of dizziness in multiple sclerosis.  2:21-28. 2013

The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics..  1:81-86. 2012

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.  1:81-86. 2012